HRMY — Harmony Biosciences Holdings Inc. stock price and chart

HRMY

$38.70+3.09%

as of close, Oct 20, 2026

☾ AH $38.70 +3.09%

Harmony Biosciences Holdings Inc.Stock · HealthcareRussell 2000 · 0.05% of IWMNasdaq Composite · 0.005% of ONEQUS Stock Market · 0.002% of VTIRussell 3000 · 0.002% of IWV

PeersMRNALLYMDTUNHJNJTMO

Share this page

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Aug 24, 2020

VolumeEEEEEEEEEEE

20202022202320252026

20.025.030.035.040.045.050.055.060.0010.0M$38.70

2026-10-20

Price$38.70

MA20$38.72

MA50$34.75

Vol1.8M

What would $1,000 invested in HRMY be worth today? →

HRMY returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $38.70
YTD price return: +3.42%
YTD total return: +3.42%
Next earnings: Nov 3, 2026
Market cap: 2.3B2020-09 1.9B2026-10 2.3B+16.9% over the window
Enterprise value: 1.7B
Shares outstanding: 58.2M2019-12 7.8M2026-06 58.2M+647.8% over the window
52W low: $25.52
52W high: $43.49
From 52W high: -11.01%
From 52W low: +51.65%
52W range: 73%

Volume

Rel volume: 0.80×
30D volume: 1M
30D $ vol: 40.4M

Fundamentals

Sales (ttm): 959.9M2019-12 6M2026-06 959.9M+15911.6% over the window
Sales/share: $16.482019-12 $0.772026-06 $16.48+2041.1% over the window
EPS (ttm): $3.102019-12 -$24.072026-06 $3.10-112.9% over the window
FCF (ttm): 347.9M2019-12 -75.6M2025-12 347.9M-560.3% over the window
FCF/share: $5.972019-12 -$9.712025-12 $6.01-162.0% over the window
Book value/share: $17.162019-12 -$54.302026-06 $17.16-131.6% over the window
Net margin: 18.88%2019-12 -2535.1%2026-06 18.9%-100.7% over the window
ROE: 18.14%2020-12 -38.0%2026-06 18.1%-147.7% over the window
ROA: 13.20%2019-12 -142.4%2026-06 13.2%-109.3% over the window
Debt / equity: 0.13×2020-09 2.042026-06 0.13-93.4% over the window
Current ratio: 3.482019-12 1.582026-06 3.48+119.7% over the window

Growth (CAGR, ttm) · 10Y

Sales: +24.27%2025-06-30 → 2026-06-30772.5M → 959.9M (+24.3% total)+24.37%2023-06-30 → 2026-06-30498.9M → 959.9M (+92.4% total)+32.47%2021-06-30 → 2026-06-30235.4M → 959.9M (+307.8% total)n/a
Net income: +0.20%2025-06-30 → 2026-06-30180.9M → 181.3M (+0.2% total)-3.26%2023-06-30 → 2026-06-30200.2M → 181.3M (-9.5% total)+50.86%2021-06-30 → 2026-06-3023.2M → 181.3M (+681.2% total)n/a
FCF: +59.15%2024-12-31 → 2025-12-31218.7M → 347.9M (+59.1% total)+34.08%2022-12-31 → 2025-12-31144.3M → 347.9M (+141.1% total)n/an/a
Shares: +1.22%2025-06-30 → 2026-06-3057.5M → 58.2M (+1.2% total)-0.99%2023-06-30 → 2026-06-3060M → 58.2M (-2.9% total)+0.43%2021-06-30 → 2026-06-3057M → 58.2M (+2.2% total)n/a

Per-share growth (CAGR, ttm) · 10Y

EPS: -0.20%2025-06-30 → 2026-06-30$3.10 → $3.10 (-0.2% total)-1.83%2023-06-30 → 2026-06-30$3.27 → $3.10 (-5.4% total)+50.88%2021-06-30 → 2026-06-30$0.40 → $3.10 (+681.7% total)n/a
Sales/share: +22.77%2025-06-30 → 2026-06-30$13.43 → $16.48 (+22.8% total)+25.62%2023-06-30 → 2026-06-30$8.31 → $16.48 (+98.2% total)+31.90%2021-06-30 → 2026-06-30$4.13 → $16.48 (+299.2% total)n/a
FCF/share: +57.78%2024-12-31 → 2025-12-31$3.81 → $6.01 (+57.7% total)+35.44%2022-12-31 → 2025-12-31$2.42 → $6.01 (+148.5% total)n/an/a
Book value/share: +27.71%2025-06-30 → 2026-06-30$13.44 → $17.16 (+27.7% total)+28.50%2023-06-30 → 2026-06-30$8.09 → $17.16 (+112.2% total)+50.54%2021-06-30 → 2026-06-30$2.22 → $17.16 (+672.9% total)n/a
Price: +48.77%2025-10-20 → 2026-10-20$26.02 → $38.70 (+48.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+24.34%2023-10-20 → 2026-10-20$20.13 → $38.70 (+92.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-1.61%2021-10-20 → 2026-10-20$41.98 → $38.70 (-7.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +48.77%2025-10-20 → 2026-10-20$26.02 → $38.70 (+48.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+24.34%2023-10-20 → 2026-10-20$20.13 → $38.70 (+92.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-1.61%2021-10-20 → 2026-10-20$41.98 → $38.70 (-7.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 12.5×2020-09 -12.692026-10 12.43-198.0% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 9.8×2020-09 -13.222026-10 9.77-173.9% over the window
Fwd P/E: 5.4×
P/S (ttm)Market cap ÷ TTM revenue.: 2.3×2020-09 321.692026-10 2.35-99.3% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 2.3×2020-09 20.402026-10 2.26-88.9% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 6.5×2020-09 -25.512026-10 6.48-125.4% over the window
EV/EBITDA (fy): 7.5×
EV/Sales (ttm): 1.8×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 15.44%2020-12 -0.1%2025-12 16.1%-11166.9% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 58.2M ÷ 57.5M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -1.22%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-1.22%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($1.8B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -1.22%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($2.3B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2020-12 -6.6%2026-06 0.0%-100.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($2.3B). Same caveat as the cash buyback yield.: 0.00%2020-12 -6.6%2026-06 0.0%-100.0% over the window

Vs own 10Y history

P/E: 34th
P/OI: 29th
P/S: 13th
P/B: 11th
P/FCF: 15th

Bar = where today’s multiple sits in HRMY’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-20#

+3.09%

+4.51%

-7.90%

+15.52%

YTD

+3.42%

+48.73%

-7.81%

Financial statements

Open full HRMY financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+11.34%	+3.49%
JNJ	Johnson & Johnson	-3.94%	+2.19%
ABBV	AbbVie Inc.	+9.52%	+2.26%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+11.24%	+3.04%
MRK	Merck & Co. Inc.	+0.97%	+3.25%
NVS	Novartis AG	+9.45%	+2.29%
TMO	Thermo Fisher Scientific Inc.	+5.51%	+1.18%
AMGN	Amgen Inc.	+13.82%	+3.29%

HRMY — Harmony Biosciences Holdings Inc. price, chart and key statistics